Cargando…

Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD

Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liesen, Michael P., Noonan, Megan L., Ni, Pu, Agoro, Rafiou, Hum, Julia M., Clinkenbeard, Erica L., Damrath, John G., Wallace, Joseph M., Swallow, Elizabeth A., Allen, Matthew R., White, Kenneth E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163801/ https://www.ncbi.nlm.nih.gov/pubmed/35656701 http://dx.doi.org/10.14814/phy2.15307

Ejemplares similares

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
por: Noonan, Megan L., et al.
Publicado: (2020)

SUN-351 Sex Is a Strong Variable in the Mineral Metabolism Defects and Endocrine Dysfunction Associated with the Murine Adenine Diet Model of Chronic Kidney Disease (CKD)
por: Liesen, Michael P, et al.
Publicado: (2020)

Osteocytic FGF23 and Its Kidney Function
por: Agoro, Rafiou, et al.
Publicado: (2020)

Osteocyte Egln1/Phd2 links oxygen sensing and biomineralization via FGF23
por: Noonan, Megan L., et al.
Publicado: (2023)

C-FGF23 peptide alleviates hypoferremia during acute inflammation
por: Agoro, Rafiou, et al.
Publicado: (2020)

Clinical Significance of FGF-23 in Patients with CKD
por: Russo, Domenico, et al.
Publicado: (2011)

FGF23 and Phosphate–Cardiovascular Toxins in CKD
por: Vogt, Isabel, et al.
Publicado: (2019)

Iron Supplementation Therapy, A Friend and Foe of Mycobacterial Infections?
por: Agoro, Rafiou, et al.
Publicado: (2019)

FGF-23 and sclerostin in serum and bone of CKD patients
por: Lima, Florence, et al.
Publicado: (2023)

Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice
por: Murali, Sathish K., et al.
Publicado: (2016)

Antiviral effects of ferric ammonium citrate
por: Wang, Hongbin, et al.
Publicado: (2018)

Physicochemical characterization of ferric pyrophosphate citrate
por: Gupta, Ajay, et al.
Publicado: (2018)

Ferric pyrophosphate citrate: interactions with transferrin
por: Pratt, Raymond, et al.
Publicado: (2018)

In the COVID-19 era, let’s keep an eye on clinical trials in Africa
por: Agoro, Rafiou
Publicado: (2020)

Ferric citrate is a safe and digestible source of iron in broilers and piglets
por: Männer, Klaus, et al.
Publicado: (2021)

An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023)

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
por: Bech, Anneke P., et al.
Publicado: (2015)

Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
por: Ganz, Tomas, et al.
Publicado: (2019)

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial
por: Hanudel, Mark R., et al.
Publicado: (2022)

Cell iron status influences macrophage polarization
por: Agoro, Rafiou, et al.
Publicado: (2018)

Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats
por: IIDA, Akio, et al.
Publicado: (2020)

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017)

Ferric Citrate Uptake Is a Virulence Factor in Uropathogenic Escherichia coli
por: Frick-Cheng, Arwen E., et al.
Publicado: (2022)

Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022)

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease
por: Wu, Mei-Yi, et al.
Publicado: (2017)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017)

Reduction of costs for anemia-management drugs associated with the use of ferric citrate
por: Thomas, Anila, et al.
Publicado: (2014)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
por: Hain, Debra J., et al.
Publicado: (2017)

Non-Transferrin-Bound Iron (NTBI) Uptake by T Lymphocytes: Evidence for the Selective Acquisition of Oligomeric Ferric Citrate Species
por: Arezes, Joao, et al.
Publicado: (2013)

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

Nasal delivery of nanoliposome-encapsulated ferric ammonium citrate can increase the iron content of rat brain
por: Guo, Xueling, et al.
Publicado: (2017)

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model
por: Mutell, Richard, et al.
Publicado: (2013)

A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model
por: Dai, Bing, et al.
Publicado: (2012)

Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)(2)D and normal FGF7 concentrations characterize patients with CKD
por: Kritmetapak, Kittrawee, et al.
Publicado: (2021)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease
por: Hanudel, Mark R., et al.
Publicado: (2022)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ejdqulnc05gugnre1p93t7ke4f